CD33 and acute myeloid leukemia: In vitro experiments, the CiTE antibody indeed showed a potent ability to activate T cells with an increased level of IFN -γ and cause cytotoxic lysis with high specificity for both CD33 + PD-L1 + cells and patient-derived AML cells [134].